Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Accured Expenses (2018 - 2025)

Serina Therapeutics' Change in Accured Expenses history spans 8 years, with the latest figure at -$183000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 194.82% year-over-year to -$183000.0; the TTM value through Sep 2025 reached -$30000.0, down 155.56%, while the annual FY2024 figure was $400000.0, 385.71% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$183000.0 at Serina Therapeutics, down from $273000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $540000.0 in Q4 2021 and bottomed at -$464000.0 in Q2 2024.
  • The 5-year median for Change in Accured Expenses is -$2000.0 (2022), against an average of -$6368.4.
  • The largest annual shift saw Change in Accured Expenses plummeted 3800.0% in 2023 before it surged 443.59% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $540000.0 in 2021, then plummeted by 100.37% to -$2000.0 in 2022, then tumbled by 3800.0% to -$78000.0 in 2023, then soared by 443.59% to $268000.0 in 2024, then crashed by 168.28% to -$183000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Change in Accured Expenses are -$183000.0 (Q3 2025), $273000.0 (Q2 2025), and -$388000.0 (Q1 2025).